Affordable Access

Access to the full text

Oxidation Products of Uric Acid and Ascorbic Acid in Preterm Infants with Chronic Lung Disease

Authors
  • Ogihara, Tohru
  • Kim, Han-Suk
  • Hirano, Kazuya
  • Imanishi, Miho
  • Ogihara, Hiromi
  • Tamai, Hiroshi
  • Okamoto, Ryozo
  • Mino, Makoto
Type
Published Article
Journal
Neonatology
Publisher
S. Karger AG
Publication Date
Dec 19, 1997
Volume
73
Issue
1
Pages
24–33
Identifiers
DOI: 10.1159/000013956
Source
Karger
Keywords
License
Green
External links

Abstract

Allantoin, the oxidation product of uric acid (UA), can be used as an in vivo marker of free radical generation. The aims of the present study were to evaluate the allantoin changes in plasma and bronchoalveolar lavage fluid (BALF) as well as to examine plasma levels of ascorbic acid (AA) and its oxidation product, dehydroascorbic acid (DHAA), in infants with or without chronic lung disease (CLD) during the first week of life. The study population was 20 infants of 24–30 weeks gestation, comprising 10 who subsequently developed CLD and 10 without CLD. In the CLD infants, the plasma allantoin/UA ratio showed a significant increase after day 1 and continued to increase gradually to reach a peak on day 6 (6.5 ± 4.1% for CLD and 2.1 ± 0.9% for non-CLD infants). The allantoin/UA ratio in BALF was also higher in CLD infants and the difference reached significance on days 4–6 (41.2 ± 15.8% for CLD and 11.7 ± 9.9% for non-CLD infants). In contrast to allantoin, the plasma DHAA/AA ratio did not differ between the 2 groups throughout the study period. Our findings that the allantoin/UA ratios were significantly higher in CLD than non-CLD infants not only in plasma but also in BALF, and that the intergroup differences of this ratio in both plasma and BALF was more prominent in the latter half of the first week of life further confirm our previous speculation that oxygen radicals are involved in the development of neonatal CLD.

Report this publication

Statistics

Seen <100 times